Drug Profile

Nimotuzumab - InnoMab

Alternative Names: BIOMAb EGFR; CIMAher; Cimaher; DE-766; h-R3; KI-0501; KI-0502; OSAG101; Taixinsheng; TheraCIM; TheraCIM hR3; Theraloc; VECTHIX

Latest Information Update: 21 Jan 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Center of Molecular Immunology; CIMYM
Developer Biocon Biopharmaceuticals; Biotech Pharmaceutical; Center of Molecular Immunology; CIMYM; Daiichi Sankyo Inc; Eurofarma; Gilead Sciences; Innogene Kalbiotech; InnoMab; Kuhnil Pharmaceutical Company; Laboratorios Pisa; Oncoscience
Class Antineoplastics; Immunotherapies; Monoclonal antibodies
Mechanism of Action Epidermal growth factor receptor antagonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Pancreatic cancer; Glioma
New Molecular Entity Yes

Marketed Anaplastic astrocytoma; Brain cancer; Glioblastoma; Glioma; Head and neck cancer; Nasopharyngeal cancer; Oesophageal cancer
Phase III Adenocarcinoma; Cervical cancer; Non-small cell lung cancer; Pancreatic cancer; Squamous cell cancer
Phase II/III Triple negative breast cancer
Phase II Colorectal cancer
No development reported Breast cancer; Gastric cancer; Polycystic kidney disease; Prostate cancer
Discontinued Brain metastases

20 Jan 2025 Biotech Pharmaceutical plans a phase II trial for Pancreatic cancer (Combination therapy) in China in January 2025 (NCT06781086)
06 Dec 2024 Biotech Pharmaceutical completes a phase-III clinical trials in Squamous cell cancer (Combination therapy, Late-stage disease, Recurrent) in China (IV) (NCT06781073)
01 Aug 2024 Phase-III clinical trials in Adenocarcinoma (Combination therapy, Metastatic disease, Second-line therapy or greater) in China (IV) (NCT05978050)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com